Madrigal Pharma (MDGL) Confirms FDA Approval of Rezdiffra for Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis

Citi Closes 30-Day Upside Catalyst Watch on Madrigal Pharmaceuticals (MDGL)

March 18, 2024 4:04 PM EDT

Citi analyst David Lebowitz reiterated a Buy rating and $389.00 price target on Madrigal Pharmaceuticals (NASDAQ: MDGL).

The analyst comments "We are closing our Catalyst Watch for Madrigal following the approval of Rezdiffra (resmetirom) for the treatment of noncirrhotic nonalcoholic steatohepatitis (NASH, also known as metabolic... More

Madrigal Pharmaceuticals (MDGL) PT Raised to $425 at H.C. Wainwright, 'Rezdiffra Achieves Landmark Approval'

March 15, 2024 6:11 AM EDT

H.C. Wainwright analyst Ed Acre raised the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $425.00 (from $405.00) while maintaining a Buy rating.

The analyst comments "Rezdiffra approved with a strong label that represents the "best case" for Madrigal's commercial opportunity. Yesterday, in a widely anticipated decision, Madrigal announced that the FDA has granted accelerated approval to Rezdiffra (resmetirom) as the first ever drug for MASH (formerly, NASH). We view the label as broad and highly supportive of the use of Rezdiffra as a foundational therapy in NASH patients with significant fibrosis. Specifically, the... More

Madrigal Pharmaceuticals (MDGL) PT Raised to $389 at Citi

March 15, 2024 3:49 AM EDT

Citi analyst David Lebowitz raised the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $389.00 (from $382.00) while maintaining a Buy rating.

The analyst comments "Madrigal announced that Rezdiffra (Resmetirom) was approved as the first therapy to treat non-cirrhotic non-alcoholic steatohepatitis (NASH, also known as metabolic... More

Madrigal Pharma (MDGL) option implied volatility into FDA approval

March 14, 2024 3:51 PM EDT

Madrigal Pharma (NASDAQ: MDGL) 30-day option implied volatility is at 151; compared to its 52-week range of 49 to 176 into FDA approves Madrigal Pharmaceuticals' Rezdiffra.

... More

Madrigal Pharma (MDGL): FDA Approves rezdiffra

March 14, 2024 3:45 PM EDT

(Updated - March 14, 2024 3:52 PM EDT)

Madrigal Pharma (NASDAQ: MDGL): FDA Approves rezdiffra - website.

Rezdiffra indicated in conjunction with diet, exercise for treatment of adults with NASH with moderate to advanced liver fibrosis.
... More

Madrigal Gets FDA Approval For NDA For Rezdiffra

March 14, 2024 3:45 PM EDT

Madrigal Gets FDA Approval For NDA For Rezdiffra

... More

Madrigal Pharma (MDGL) Halted, News Pending

March 14, 2024 3:30 PM EDT

Madrigal Pharma (NASDAQ: MDGL) Halted, News Pending

... More